Savara Inc
SVRA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SVRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SVRA
Savara Inc (SVRA) is a clinical-stage biopharmaceutical company focused on developing inhaled molgramostim (MOLBREEVI) for autoimmune pulmonary alveolar proteinosis (aPAP), with no approved products or revenue to date.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.08B
Cash Runway
16.9 moLead Asset
molbreevi (Phase 3)
Next Catalyst
Phase3_Topline · May 30, 2027Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 7 clinical trials · 2 catalysts for Savara Inc.
Savara Inc (SVRA) is a clinical-stage biopharmaceutical company focused on developing inhaled molgramostim (MOLBREEVI) for autoimmune pulmonary alveolar proteinosis (aPAP), with no approved products or revenue to date.
- No revenue from product sales; company is pre-commercial and expects expenses to increase with ongoing development and manufacturing activities [sec_mda · as of 2026-08-11].
- Cash and equivalents of $41.8M as of 2026-06-30 [sec]; accumulated deficit of approximately $460.2M as of September 30, 2024 [sec_mda · as of 2024-11-12].
- Two Phase 3 topline readouts for inhaled molgramostim are expected: one on 2027-05-30 and another on 2027-12-01 [upcoming catalysts].
- Company has not generated any revenue and does not expect to generate revenue unless and until regulatory approval is obtained and the product is commercialized [sec_mda · as of 2026-08-11].
What works
- Cash position of $41.8M as of 2026-06-30 provides near-term operational runway for ongoing clinical trials [sec].
- Two Phase 3 trials are underway with topline data expected in 2027, representing potential value inflection points [upcoming catalysts].
- Company has raised significant capital historically, including approximately $140M in net proceeds from a public offering [sec_mda · as of 2025-11-12].
What to weigh
- No revenue from product sales; company is entirely dependent on successful development and regulatory approval of its sole product candidate [sec_mda · as of 2026-08-11].
- Accumulated deficit of approximately $460.2M as of September 30, 2024, reflecting years of losses with no near-term revenue expected [sec_mda · as of 2024-11-12].
- Future funding may be needed; company acknowledges it may need additional capital to fund development, regulatory, and commercialization activities [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Company has no revenue from product sales and expects expenses to increase.
“We have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales.”
SEC MD&A · August 11, 2026
Accumulated deficit as of September 30, 2024.
“accumulated deficit of approximately $460.2 million”
SEC MD&A · November 12, 2024
Catalyst timeline
- 2027-05-30 · Phase3_Topline — Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Neb — First Phase 3 topline readout for inhaled molgramostim in autoimmune PAP; results will inform efficacy and safety.
- 2027-12-01 · Phase3_Topline — Phase 3 Topline: An Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Inhaled Molgramosti — Second Phase 3 topline readout; open-label study design may provide additional supportive data.
Risks & what to watch (3)›
Key risks
- No approved products or revenue — Company has no revenue from product sales and does not expect any until regulatory approval is obtained [sec_mda · as of 2026-08-11].
- Clinical trial failure risk — Phase 3 topline results are pivotal; failure could materially impact the company's prospects [upcoming catalysts].
- Need for additional funding — Company may need to raise additional capital to fund development and commercialization [sec_mda · as of 2026-08-11].
What to watch
- Phase 3 topline data for inhaled molgramostim in aPAP expected on 2027-05-30 [upcoming catalysts].
- Second Phase 3 topline data expected on 2027-12-01 [upcoming catalysts].
- Cash burn rate and any future financing activities given $41.8M cash as of 2026-06-30 [sec].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Savara Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Savara Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
16.9 months
D/E 0.34 · 0% dilution
Lead: Phase 3
2 candidates
2 upcoming, next in ~273d
0 buys · 1 sell (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
180
Total value held
$762.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 15,567,826 | $85.0M |
| deerfield management company, l.p. | 13,569,000 | $74.1M |
| blackrock, inc. | 11,291,185 | $61.6M |
| polar capital holdings plc | 9,541,786 | $52.1M |
| woodline partners lp | 8,490,238 | $46.4M |
| state street corp | 6,707,684 | $36.6M |
| rtw investments, lp | 5,952,380 | $32.5M |
| marshall wace, llp | 4,514,348 | $24.6M |
| geode capital management, llc | 3,594,480 | $19.6M |
| spruce street capital lp | 3,383,175 | $18.5M |
Showing top 10 of 180 institutional holders of Savara Inc. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 15.6%
- Days to cover
- 15.0
- Shares short
- 27,429,578
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SVRA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Savara Inc?
Savara Inc (SVRA) is a clinical-stage biopharmaceutical company focused on developing inhaled molgramostim (MOLBREEVI) for autoimmune pulmonary alveolar proteinosis (aPAP), with no approved products or revenue to date.
What is Savara Inc's lead drug candidate?
Savara Inc's most advanced tracked candidate is molbreevi (Phase 3) for autoimmune pulmonary alveolar proteinosis (aPAP).
What is Savara Inc's next catalyst?
Savara Inc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Neb" — expected May 30, 2027.
Who is the CEO of Savara Inc?
Mr. Matthew Pauls J.D., M.B.A. is the chief executive officer of Savara Inc (SVRA).
Where is Savara Inc headquartered?
Savara Inc (SVRA) is headquartered in Yardley, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.